I
ntracerebral hemorrhage (ICH) is a major cause of adult morbidity and mortality. The 30-day mortality associated with spontaneous ICH is ≈40% and a majority of survivors are functionally dependent at long-term follow-up. 1 Studies focusing on halting hematoma expansion, hemostatic medications, and hematoma evacuation surgery have failed to show clinical benefit. 2, 3 Besides aggressive blood pressure control, which showed a tendency toward improved outcome, 4 there are no proven treatment strategies to improve outcome after ICH, and comprehensive medical management is recommended. 5 A mainstay of medical management in ICH is prevention of venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE). Patients with ICH are at high risk for DVT and PE, with 4-fold higher rates than in patients with acute ischemic stroke. 6, 7 Prophylaxis for VTE includes sequential compression devices (nonpharmacological) and low-dose anticoagulant medications (pharmacological). American Heart Association/ American Stroke Association guidelines have recommended low-dose unfractionated heparin or low-molecular weight heparin use early after ICH since 2007 8 and currently recommend initiation between 1 and 4 days after ICH onset and after cessation of active bleeding (class IIb, level of evidence B). 5 However, real-world compliance with this recommendation is unknown. Using the Premier database, we evaluated patient, hospital, and geographic factors associated with prophylactic anticoagulation after ICH in the United States.
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hospitalized patients at 506 hospitals across the United States, representing ≈15% of hospital discharges annually. All billing and administrative coding information can be cross-linked to hospital pharmacy billing records. Previous studies suggest that hospital and patient characteristics in Premier are representative of the US population, 9 although it may over-represent larger, teaching hospitals (Table 1) . Unlike other large administrative data sets, such as MedPar, an advantage of Premier is that it includes all payors, has pharmacy drug use data, and is not limited to the Medicare-eligible patient population.
Using the Premier database, we identified all adult patients (>18 years) with ICH by primary or admitting International Classification of Diseases Ninth edition (ICD-9) code 431 between January 1, 2006, and December 31, 2010 ( Figure I in the online-only Data Supplement). We included only patients who survived to day 2 of hospitalization. We excluded those patients who underwent craniotomy (ICD-9 procedure code 01.2x), cerebral angiography (88.41), or had traumatic brain injury (850.xx to 854.xx); they were deemed more likely to harbor secondary causes of ICH, have contraindications to anticoagulation in the acute period, or be subarachnoid hemorrhage misclassified as ICH. We also excluded those patients given warfarin during the hospital stay because these patients probably required therapeutic anticoagulation for conditions, such as atrial fibrillation.
Variables
Type of anticoagulant used and date of first administration was captured if a patient was billed for heparin (in any form besides intravenous flush), enoxaparin, dalteparin, ardeparin, tinzaparin, or fondaparinux (the study period predated the release of any of the novel anticoagulant medications). Doses were not available but were assumed to be prophylactic doses. Date of first administration was transformed into hospital day with day 0 being the day of admission. Other covariates of interest included hospital characteristics, such as location (rural versus urban), academic or teaching (versus nonteaching) status as defined by Premier, geographic location in the United States (Northeast, Midwest, South, and West), number of beds, and annual ICH case volume; and patient characteristics, such as demographics (age, sex, race, and ethnicity), type of insurance, baseline medical risk factors (diabetes mellitus, hypertension, congestive heart failure, atrial fibrillation, coronary artery disease, previous VTE, and smoking history as defined by ICD-9 codes), location where patient first received care, and patient location of initial care. Data on day of week and time of arrival (daytime or not) were not available.
Statistical Analysis
Data are expressed as number (percent), mean (SD), or median (interquartile range) as appropriate. The Kolmogorov-Smirnov test was used to assess for normality of continuous data distribution. Frequency of anticoagulant use overall and by hospital day is reported. We assessed for differences in baseline patient and hospital characteristics and anticoagulant use after ICH using χ 2 test for categorical variables, t test for normally distributed continuous variables, and Mann-Whitney U test for ordinal variables and non-normally distributed continuous variables. Multivariable logistic regression was used to estimate odds ratios and 95% confidence intervals for independent predictors of prophylactic anticoagulant use after ICH. Candidate variables for the initial model were selected based on univariate strength of association and plausibility. However, those with <5% prevalence in this population were not included. A P<0.05 was considered statistically significant. Analysis and data management was performed using SAS, version 9.3 and SAS Enterprise guide, version 4.3.
Results
There were 32 690 inpatient records during the study period meeting our inclusion/exclusion criteria. The most commonly used agents were as follows: heparin (71.1%), enoxaparin (27.5%), and dalteparin (1.4%). Approximately 45% of those receiving prophylactic anticoagulation were initiated before day 2 increasing to 67% by day 4, and 91% by day 11 (Figure 1 ). During the study period, there was no trend suggesting an increase in use within 2 days overall (P=0.42); however, among those receiving prophylactic anticoagulation at any time during hospitalization (n=5395), use within 2 days actually declined over time (P<0.01 for trend; Figure 2 ).
Using bivariate analysis ( In multivariable analysis (Table 3) , in addition to several patient factors (age, race and ethnicity, insurance status, arrival location, and medical risk factors) and hospital factors (urban location and bed size), geographic region remained independently associated with prophylactic anticoagulation after ICH. Compared with Western states, patients treated at hospitals in Northeastern (adjusted odds ratio, 2.30; 95% confidence intervals, 2.07-2.56) and Southern (adjusted odds ratio, 1.59; 95% confidence intervals, 1.43-2.76) states were more likely to receive prophylactic anticoagulation.
Discussion
We found that prophylactic anticoagulation is used in <20% of patients with ICH. Early prophylactic anticoagulation (within 2 days) was provided in <10% of patients with ICH overall and actually declined during the 5-year study period among the subset of patients who received any prophylactic anticoagulation. Besides patient and hospital characteristics typical of urban and academic centers (ie, younger age, minorities, presence of vascular risk factors, and larger urban hospitals), we also observed geographic variation such that Northeastern hospitals were more likely to provide prophylactic anticoagulation than other regions of the United States. Despite guidelines supporting the practice, our findings suggest that DVT prophylaxis after ICH may be suboptimal nationwide.
Multiple studies have observed that hematoma expansion is infrequently encountered after the first 24 to 48 hours in spontaneous patients with ICH. 10, 11 In contrast, clinically evident VTE occurs in up to 13% of patients with ICH, peaks between days 2 and 7 of hospitalization, and carries a high risk of fatality because of PE. [12] [13] [14] [15] However, large randomized clinical trials of pharmacological DVT prophylaxis in patients with ICH have not been conducted. Several observational and 
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nonrandomized studies have indicated that low-dose anticoagulation does not result in hematoma expansion after ICH. [16] [17] [18] [19] [20] [21] Three small randomized trials have also been completed. [22] [23] [24] In 68 patients with ICH, low-dose heparin starting on day 2 led to a statistically lower rate of PE when compared with 4th or 10th day of initiation. 24 The second trial included 46 patients and found that low-dose subcutaneous heparin did not increase risk of rebleeding or hematoma expansion. 23 A more recent trial of 75 patients using enoxaparin also observed no increase risk of hematoma expansion. 22 A meta-analysis of 4 controlled (2 randomized) 17, 21, 22, 24 studies suggested a significant reduction in PE with prophylactic anticoagulation with no effect on DVT occurrence or bleeding. 25 Despite previous studies showing modest benefits in reducing PE balanced partly by risk of bleeding in medically ill and hospitalized patients with stroke, [26] [27] [28] current American Heart Association/American Stroke Association guidelines recommend prophylactic anticoagulation (class I, level of evidence A) in immobilized patients with acute ischemic stroke. 29 In contrast, guidelines for ICH management convey more uncertainty. Multiple organizations in the United States (since 2007), Europe (since 2006), and Japan (since 2011) recommend that prophylactic doses of unfractionated heparin or low-molecular weight heparin be considered for DVT prevention, 5,30-32 whereas prophylactic anticoagulation is not recommended in the United Kingdom or Australia. 33, 34 Furthermore, current Joint Commission guidelines include pneumatic compression devices and prophylactic anticoagulation as acceptable forms of DVT prophylaxis, whereas excluding compression stockings as clearly inappropriate. 
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The strength of these recommendations, in addition to the discrepancies, may be deterring more widespread implementation in practice.
There have been, to our knowledge, no previous reports on nationwide use of prophylactic anticoagulation after ICH. Our results indicate that widespread acceptance of the current US guidelines is low, particularly at nonacademic or rural centers. Although we cannot explain the geographic or hospital-level variations or overall underuse, we speculate that physician lack of awareness of the evidence and guidelines, preferences toward nonpharmacological prophylaxis, or safety concerns about pharmacological prophylaxis probably play major roles in decision-making. Indeed, the decline in early prophylactic anticoagulation suggests increased safety concerns as a potential reason. A lack of specialists with expertise in managing patients with ICH and lower annual volume of patients with ICH may also contribute to inexperience and unease with this practice guideline at smaller hospitals. Specialists in stroke and neurocritical care, who tend to be clustered at larger urban and academic hospitals, may be more familiar with guidelines and also have greater experience with safe initiation of prophylactic anticoagulation after ICH. Alternatively, the lack of large definitive randomized controlled trials to support stronger recommendations may be driving practice in the community.
Our study has several strengths and limitations. First, by using a large nationwide database with linked pharmacy records, we were able to estimate anticoagulant use and date of first administration with high accuracy. Second, we were able to assess temporal and geographic variation with large sample sizes. However, because our analysis relies on administrative data compiled by ICD-9 codes, we are subject to the potential for case ascertainment errors. We cannot be certain that our included cohort contains only patients with spontaneous ICH, the population of primary interest because these patients would have few or no contraindications to low-dose anticoagulation. However, the positive predictive value of ICD-9 coding of ICH (431.x) has been previously shown to be modest (75%-77%) with errors predominantly being because of misclassification with subarachnoid hemorrhage and ischemic stroke with hemorrhagic transformation.
36,37 An underestimation of the true use of prophylactic anticoagulation for ICH would exist in the case of misclassification of ischemic stroke with hemorrhagic transformation as ICH in our data. We also excluded patients who underwent cerebral angiography, as these may include secondary causes of ICH (ie, arteriovenous malformation) and also aneurysmal subarachnoid hemorrhage. Because clinical and imaging data are not available, we cannot comment on the size, location, intraventricular extension, presumed cause, or stability of the hematoma or the clinical severity of the presentation. Stroke or coma scales and other surrogates of disease severity were not available in the Premiere database; therefore, we are not able to adjust for or stratify by clinical severity. We did, however, exclude those patients who did not survive to day 2, a group likely to have been too severe to justify prophylactic anticoagulation. We did not exclude patients with external ventricular drains or other surgical procedures, besides craniotomy, that might delay or contraindicate anticoagulant use. Likewise, we could not adjust for other clinical risk factors, such as family history of VTE, body mass index or known contraindications to prophylactic anticoagulation, such as systemic bleeding or early ambulatory status. Individualized decision-making probably occurs such that factors associated with increased risk of VTE (ie, prolonged immobility, cancer, or hypercoagulable state) or hemorrhagic complication (ie, coagulopathy or active bleeding) are carefully considered. We are unable to correlate administration or timing of prophylactic anticoagulation with measures of efficacy (occurrence of acute DVT or PE) or with adverse events (occurrence of hematoma expansion or recurrent bleeding) during hospitalization or beyond. Finally, we cannot comment on nonpharmacological prophylaxis (ie, sequential compression devices), which afford some protection from VTE. These limitations are unlikely to explain our main finding of <20% prophylactic anticoagulation use after ICH.
Conclusions
In a large nationwide registry, we observed that prophylactic anticoagulation was provided to less than one-fifth of patients with ICH. Our results suggest that current guidelines are not accepted broadly in clinical practice, which may be because of the strength of the recommendations, lack of knowledge or expertise, or concerns about safety. Further analysis of practitioner preferences and perceptions may help guide next steps. These may include targeted dissemination and education. Adj. OR indicates adjusted odds ratio; CAD, coronary artery disease; CHF, congestive heart failure; CI, confidence intervals; ED, emergency department; and ICH, intracerebral hemorrhage.
*Variables entered into the full model: age, sex, race, Medicaid, teaching hospital, ED arrival, diabetes mellitus, hypertension, CHF, atrial fibrillation, CAD, urban/rural, region, and hospital volume (beds).
Stroke
February 2015
However, larger randomized clinical trials may be required to change current perception of clinical equipoise.
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